Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.
Front Immunol. 2022 Apr 25;13:878812. doi: 10.3389/fimmu.2022.878812. eCollection 2022.
There is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients.
A prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed.
Patients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors ( = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection (< 0.001), and than patients who required oxygen therapy (< 0.05), and had 5-fold higher IgG1 titers than RF non-survivors (< 0.001) and those who needed oxygen therapy (< 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission (< 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived ( = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p ≤ 0.0036).
We demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection.
有大量证据表明,SARS-CoV-2 特异性体液免疫反应与预防重症疾病有关。然而,关于未免疫患者入院时的体液免疫反应与疾病严重程度的相关性,数据相对较少。我们的目标是确定体液免疫反应的变量,这些变量可能成为未接种疫苗的 SARS-CoV-2 患者 COVID-19 进展的预后标志物。
对来自 12 月 10 日大学医院的 160 名未免疫的成年 COVID-19 患者进行了前瞻性横断面研究。根据疾病严重程度将参与者分为以下四个临床组:发生呼吸衰竭(RF)的非幸存者、幸存的 RF 患者、需要氧疗的患者和未接受氧疗的患者。入院时采集血清样本,通过 ELISA 测定 IgM、IgG、IgG 亚类抗体滴度,并使用替代中和测定法测定中和抗体滴度。分析组间抗体滴度的差异以及患者的临床和分析特征与抗体滴度之间的关系。
发生 RF 并幸存的患者的 IgM 滴度比非幸存者高 2 倍( = 0.001),比发生 RF 并感染死亡的患者总 IgG 水平高(<0.001),比需要氧疗的患者高(<0.05),比 RF 非幸存者的 IgG1 滴度高 5 倍(<0.001),比需要氧疗的患者高 2 倍(<0.05),比入院期间不需要氧疗的患者高 2 倍(<0.05)。相比之下,RF 非幸存者的中和抗体水平最低,与幸存的 RF 患者相比显著降低( = 0.03)。在总队列中,IgM、总 IgG、IgG1 和 IgG3 滴度与中和抗体滴度呈正相关(p ≤ 0.0036)。
我们证明,与感染死亡的 RF 患者相比,幸存的 RF 感染患者的 IgM、IgG、IgG1 和中和滴度显著升高,表明使用体液免疫反应变量可作为指导未免疫患者因 SARS-CoV-2 感染入院的临床管理的预后标志物。